Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury
文献类型：期刊论文
| 作者 | Li, Xiuli; Zhong, Kan; Guo, Zitao; Zhong, Dafang ; Chen, Xiaoyan
|
| 刊名 | Drug metabolism and disposition: the biological fate of chemicals
 |
| 出版日期 | 2015-11 |
| 卷号 | 43期号:11页码:1751-9 |
| ISSN号 | 1521-009X |
| DOI | 10.1124/dmd.115.064121 |
| 文献子类 | Article |
| 英文摘要 | Fasiglifam (TAK-875), a selective G-protein-coupled receptor 40 agonist, was developed for the treatment of type 2 diabetes mellitus; however, its development was terminated in phase III clinical trials because of liver safety concerns. Our preliminary study indicated that intravenous administration of 100 mg/kg of TAK-875 increased the serum total bile acid concentration by 3 to 4 times and total bilirubin levels by 1.5 to 2.6 times in rats. In the present study, we examined the inhibitory effects of TAK-875 on hepatobiliary transporters to explore the mechanisms underlying its hepatotoxicity. TAK-875 decreased the biliary excretion index and the in vitro biliary clearance of d₈-taurocholic acid in sandwich-cultured rat hepatocytes, suggesting that TAK-875 impaired biliary excretion of bile acids, possibly by inhibiting bile salt export pump (Bsep). TAK-875 inhibited the efflux transporter multidrug resistance-associated protein 2 (Mrp2) in rat hepatocytes using 5 (and 6)-carboxy-2',7'-dichlorofluorescein as a substrate. Inhibition of MRP2 was further confirmed by reduced transport of vinblastine in Madin-Darby canine kidney cells overexpressing MRP2 with IC₅₀ values of 2.41 μM. TAK-875 also inhibited the major bile acid uptake transporter Na(+)/taurocholate cotransporting polypeptide (Ntcp), which transports d₈-taurocholic acid into rat hepatocytes, with an IC₅₀ value of 10.9 μM. TAK-875 significantly inhibited atorvastatin uptake in organic anion transporter protein (OATP) 1B1 and OATP1B3 cells with IC₅₀ values of 2.28 and 3.98 μM, respectively. These results indicate that TAK-875 inhibited the efflux transporter MRP2/Mrp2 and uptake transporters Ntcp and OATP/Oatp, which may affect bile acid and bilirubin homeostasis, resulting in hyperbilirubinemia and cholestatic hepatotoxicity. |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/266335]  |
| 专题 | 上海药物代谢研究中心 |
| 通讯作者 | Chen, Xiaoyan |
| 作者单位 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China |
| 推荐引用方式 GB/T 7714 | Li, Xiuli,Zhong, Kan,Guo, Zitao,et al. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury[J]. Drug metabolism and disposition: the biological fate of chemicals,2015,43(11):1751-9. |
| APA | Li, Xiuli,Zhong, Kan,Guo, Zitao,Zhong, Dafang,&Chen, Xiaoyan.(2015).Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.Drug metabolism and disposition: the biological fate of chemicals,43(11),1751-9. |
| MLA | Li, Xiuli,et al."Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury".Drug metabolism and disposition: the biological fate of chemicals 43.11(2015):1751-9. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。